Keyphrases
Escherichia Coli
100%
Epidemiology
100%
Recurrent Urinary Tract Infections (rUTIs)
100%
Prudent Antimicrobial Use
100%
Consensus Review
100%
Asia-Pacific Region
100%
Urinary Tract Infection
75%
Imipenem
75%
Ertapenem
75%
Urinary Isolates
75%
Uncomplicated UTI
75%
Multidrug-resistant Organisms
50%
Cefepime
50%
ESBL-producing
50%
Singapore
25%
Resistance Pattern
25%
Infectious Diseases
25%
Hong Kong
25%
Risk Factors
25%
Patient Characteristics
25%
India
25%
Antimicrobial Therapy
25%
Trimethoprim-sulfamethoxazole (TMP-SMX)
25%
Aminoglycosides
25%
Antimicrobial
25%
Epidemiological Data
25%
Klebsiella Pneumoniae (K. pneumoniae)
25%
Pharmacodynamics
25%
Polymyxin B
25%
Pharmacokinetics
25%
Cephalosporins
25%
Extended-spectrum-lactamase
25%
Third-generation Cephalosporins
25%
Ceftriaxone
25%
Ciprofloxacin
25%
Fluoroquinolones
25%
Broad-spectrum Antibiotics
25%
Ceftazidime
25%
Effective Management
25%
Carbapenems
25%
Meropenem
25%
Doripenem
25%
Antimicrobial Resistance
25%
Local Resistance
25%
Severely Ill Patients
25%
Levofloxacin
25%
Financial Burden
25%
Empiric Antimicrobial Therapy
25%
Polymyxin
25%
Piperacillin-tazobactam
25%
Tigecycline
25%
Colistin B
25%
Pharmacology, Toxicology and Pharmaceutical Science
Antimicrobial Therapy
100%
Urinary Tract Infection
100%
Escherichia coli
50%
Imipenem
37%
Ertapenem
37%
Antiinfective Agent
25%
Extended Spectrum Beta Lactamase
25%
Cephalosporin Derivative
25%
Prevalence
12%
Infection
12%
Antibiotic Agent
12%
Cotrimoxazole
12%
Klebsiella pneumoniae
12%
Pharmacodynamics
12%
Pharmacokinetics
12%
Aminoglycoside
12%
Polymyxin B
12%
Penicillinase
12%
Antimicrobial Resistance
12%
Quinolone Derivative
12%
Ciprofloxacin
12%
Ceftriaxone
12%
Ceftazidime
12%
Doripenem
12%
Meropenem
12%
Colistimethate
12%
Carbapenem Derivative
12%
Cefepime
12%
Levofloxacin
12%
Polymyxin
12%
Cefotaxime
12%
Piperacillin Plus Tazobactam
12%
Tigecycline
12%